INT281889

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2008
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 1.34
Pain Relevance 0.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (PERP) Golgi apparatus (PERP) nucleolus (PERP)
plasma membrane (PERP) nucleus (PERP) cytoplasm (PERP)
Anatomy Link Frequency
thyroid 3
PERP (Homo sapiens)
Pain Link Frequency Relevance Heat
withdrawal 154 100.00 Very High Very High Very High
imagery 8 65.84 Quite High
Pain 6 12.76 Low Low
positron emission tomography 21 5.00 Very Low Very Low Very Low
headache 5 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
depression 2 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Thyroid Neoplasm 119 98.48 Very High Very High Very High
Metastasis 63 98.24 Very High Very High Very High
Thyroid Disease 26 89.28 High High
Cancer 52 86.28 High High
Disease 68 84.88 Quite High
Disease Progression 6 70.44 Quite High
Malignant Neoplastic Disease 6 37.16 Quite Low
Thrombosis 2 32.28 Quite Low
Stroke 2 31.00 Quite Low
Arthralgia 3 12.76 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Observations from other clinical trials [20-22] are not comparable with our study, and are, indeed, difficult to interpret, because of these trials' use of THW and their lengthier interval between measurements, which were conducted between RITs, i.e, months apart.
Localization (use) of THW associated with withdrawal
1) Confidence 0.35 Published 2009 Journal Thyroid Res Section Body Doc Link PMC2739165 Disease Relevance 0.28 Pain Relevance 0.08
Substitution of rhTSH stimulation for TSH stimulation by THW for diagnostic evaluations (shown in Figure 2b and reviewed by Cooper et al (2006) or for thyroid remnant ablation (shown in Figures 1c and 1d), has been published by a number of centers, allowing patients to remain on levothyroxine therapy and avoid the symptoms of hypothyroidism (Robbins et al 2001; Pacini et al 2002; Robbins et al 2002b; Barbaro et al 2003; Barbaro et al 2006; Pacini et al 2006a; Pilli et al 2007; Rosario et al 2008; Taieb et al 2008; Tuttle et al 2008).
Localization (stimulation) of THW in thyroid associated with thyroid disease and withdrawal
2) Confidence 0.29 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994210 Disease Relevance 0.45 Pain Relevance 0.10
Thyrogen® is FDA approved as an adjunct to RAI treatment of metastatic thyroid cancer only in patients who are either unable to mount an adequate endogenous TSH response to THW or in whom THW is medically contraindicated, as options are otherwise limited in that patient population.
Localization (response) of THW in thyroid associated with thyroid neoplasm and withdrawal
3) Confidence 0.29 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994210 Disease Relevance 0.31 Pain Relevance 0.14
Thyrogen® is FDA approved as an adjunct to RAI treatment of metastatic thyroid cancer only in patients who are either unable to mount an adequate endogenous TSH response to THW or in whom THW is medically contraindicated, as options are otherwise limited in that patient population.
Localization (response) of THW in thyroid associated with thyroid neoplasm and withdrawal
4) Confidence 0.29 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994210 Disease Relevance 0.31 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox